Position in ZYME
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,071,361
+$927,965 QoQ
Shares Held
42,786
+255.4% QoQ
Ownership
0.059%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
9 quarters on record
Voting authority
Sole 43%
Shared 0%
None 57%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $705,903,019 across 86 Biotechnology names. ZYME ranks #43 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
214,160 | $165,468,582 | |
| 2 | INCY |
Incyte Corp
|
1,717,978 | $161,696,089 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
212,204 | $70,211,937 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
789,429 | $51,020,796 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
1,431,071 | $29,980,937 | |
| 6 | EXEL |
Exelixis, Inc.
|
425,982 | $18,270,367 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,097,189 | $16,260,340 | |
| 8 | ARVN |
Arvinas, Inc.
|
1,441,521 | $15,280,122 |
All Filings in ZYME
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,071,361 | 42,786 | Shares | Sole | 2026-05-15 | |
| 2025-03-31 | $143,396 | 12,040 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $5,214,299 | 356,168 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $6,559,132 | 522,640 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $5,546,205 | 651,728 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $7,537,390 | 716,482 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $3,823,945 | 368,041 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $405,766 | 64,001 | Shares | Sole | 2023-11-17 | |
| 2023-06-30 | $1,554,301 | 179,896 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||